Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
REDWOOD CITY, Calif., Aug. 03, 2017 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company will be participating in the Canaccord Genuity 37th Annual Growth Conference in Boston.
Avinger management is scheduled to present on Thursday, August 10, 2017 at 10:30am ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger’s website at www.avinger.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.
About Avinger, Inc.
Founded in 2007, Avinger, Inc. is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral arterial disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through their Lumivascular platform which currently consists of the Lightbox imaging console, the Ocelot family of catheters designed for chronic total occlusions (CTOs), and Pantheris designed for atherectomy. Avinger is based in Redwood City, CA. For more information, please visit www.avinger.com.
Investor Contact: Matt Ferguson Avinger, Inc. (650) 241-7917 [email protected]
